Thermo Fisher Scientific Inc. (TMO)
Is it Worth Retaining Thermo Fisher Stock in Your Portfolio Now?
TMO continues to hold on to investors' attention due to its value-added acquisitions and trusted end-market channels.
Thermo Fisher's New Deal With CZ Imaging Institute May Boost Its Stock
TMO and CZ Imaging Institute to collaborate on further understanding of human cells.
TMO Stock Set to Gain From the Launch of New Vulcan Automated Lab
Thermo Fisher introduces the Vulcan Automated Lab to transform semiconductor analysis.
Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences
Thermo Fisher Scientific's Q4'24 and FY'24 results exceeded expectations, with revenue and profitability growing, positioning it for a potential 12% IRR long-term. Strong capital allocation, including $4.6 billion returned to shareholders and strategic acquisitions, supports Thermo Fisher's growth and undervalued stock potential. Despite weak guidance, Thermo Fisher's leadership in life sciences and pharma, along with expected 11% CAGR earnings growth, indicates a solid long-term outlook.
Billionaire Investor Buys Stocks Despite Trump's ‘Unconventional Approach'
Daniel Loeb is a brilliant billionaire investor who's invested in all sorts of market environments.
Thermo Fisher Scientific Inc. (TMO) TD Cowen 45th Annual Health Care Conference - (Transcript)
Thermo Fisher Scientific Inc. (NYSE:TMO ) TD Cowen 45th Annual Health Care Conference Call March 3, 2025 9:10 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Great. Well, welcome to the 45th Annual TD Cowen Healthcare Conference.
TMO Stock Set to Gain From The Launch of New Spatial Imaging System
Thermo Fisher's Invitrogen EVOS S1000 Spatial Imaging System addresses the limitations of current fluorescent microscopy technologies.
Thermo Fisher Scientific: Finally Ready For A Breakout? (Upgrade)
Thermo Fisher returned to growth in 4Q 2024 across all segments, and 2025 EPS growth is projected at 6.6% supported by margin expansion. Despite rich industry valuations, Thermo trades at a discount to peers like Danaher, supported by its unique scale and breadth of offerings. Thermo looks fairly valued based on a conservative DCF analysis, but its industry leadership position and relative valuation to peers warrant an upgrade to Buy.
Thermo Fisher Stock Surges as Medical Device Maker's Results Top Estimates
Shares of Thermo Fisher Scientific (TMO) rose Thursday after the medical device maker's fourth-quarter results topped analysts' estimates.
Thermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up
In the fourth quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.
Thermo Fisher (TMO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Thermo Fisher Scientific Inc. (TMO) Q4 2024 Earnings Call Transcript
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President & Chief Executive Officer Stephen Williamson - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Research Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2024 Fourth Quarter Conference call. My name is Ezra, and I will be your coordinator today.
